426
Views
85
CrossRef citations to date
0
Altmetric
Original

Overview of Tumor Cell–Based Vaccines

&
Pages 297-319 | Published online: 03 Aug 2009

REFERENCES

  • D. Jocham, A. Richter, L. Hoffmann, K. Iwig, D. Fahlenkamp, G. Zakrzewski, E. Schmitt, T. Dannenberg, W. Lehmacher, J. von Wietersheim, and C. Doehn, Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial, Lancet, 363(9409): 594–599, 2004. [CSA]
  • C.A. Uyl-de Groot, J.B. Vermorken, M.G. Hanna, Jr., P. Verboom, M.T. Groot, G.J. Bonsel, C.J. Meijer, and H.M. Pinedo, Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits, Vaccine, 23(17–18): 2379–2387, 2005. [CSA], [CROSSREF]
  • L. Shen and K.L. Rock, Priming of T cells by exogenous antigen cross-presented on MHC class I molecules, Curr. Opin. Immunol., 18(1): 85–91, 2006. [CSA], [CROSSREF]
  • M.C. Wolkers, G. Stoetter, F.A. Vyth-Dreese, and T.N. Schumacher, Redundancy of direct priming and cross-priming in tumor-specific CD + T cell responses, J. Immunol., 167(7): 3577–3584, 2001. [CSA]
  • A.Y. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science, 264(5161): 961–965, 1994. [CSA], [CROSSREF]
  • A.M. Thomas, L.M. Santarsiero, E.R. Lutz, T.D. Armstrong, Y.C. Chen, L.Q. Huang, D.A. Laheru, M. Goggins, R.H. Hruban, and E.M. Jaffee, Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients, J. Exp. Med., 200(3): 297–306, 2004. [CSA], [CROSSREF]
  • M. Nouri-Shirazi, J. Banchereau, D. Bell, S. Burkeholder, E.T. Kraus, J. Davoust, and K.A. Palucka, Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses, J. Immunol., 165(7): 3797–3803, 2000. [CSA]
  • A.F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R.M. Zinkernagel, Immune surveillance against a solid tumor fails because of immunological ignorance, Proc. Natl. Acad. Sci. U.S.A., 96(5): 2233–2238, 1999. [CSA], [CROSSREF]
  • A.F. Ochsenbein, S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel, Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction, Nature, 411(6841): 1058–1064, 2001. [CSA], [CROSSREF]
  • L. Qi, J.M. Rojas, and S. Ostrand-Rosenberg, Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo, J. Immunol., 165(10): 5451–5461, 2000. [CSA]
  • T.D. Armstrong, V.K. Clements, and S. Ostrand-Rosenberg, MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4 + T lymphocytes, J. Immunol., 160(2): 661–666, 1998. [CSA]
  • R.O. Dillman, C. DeLeon, L.D. Beutel, N.M. Barth, L.S. Schwartzberg, L.E. Spitler, D.H. Garfield, A.A. O'Connor, and S.K. Nayak, Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma, Crit. Rev. Oncol. Hematol., 39(1–2): 115–123, 2001. [CSA]
  • J. Nakashima, M. Tachibana, Y. Horiguchi, M. Oya, T. Ohigashi, H. Asakura, and M. Murai, Serum interleukin 6 as a prognostic factor in patients with prostate cancer, Clin. Cancer Res., 6(7): 2702–2706, 2000. [CSA]
  • T. Nishimura, K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta, Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo, J. Exp. Med., 190(5): 617–627, 1999. [CSA], [CROSSREF]
  • F. Fallarino, U. Grohmann, R. Bianchi, C. Vacca, M.C. Fioretti, and P. Puccetti, Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8 + T cell-dependent tumor eradication in vivo, J. Immunol., 165(10): 5495–5501, 2000. [CSA]
  • D.R. Surman, M.E. Dudley, W.W. Overwijk, and N.P. Restifo, Cutting edge: CD4 + T cell control of CD8 + T cell reactivity to a model tumor antigen, J. Immunol., 164(2): 562–565, 2000. [CSA]
  • D. Berd, H.C. Maguire, Jr., P. McCue, and M.J. Mastrangelo, Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients, J. Clin. Oncol., 8(11): 1858–1867, 1990. [CSA]
  • A. Baars, A.M. Claessen, A.J. van den Eertwegh, H.E. Gall, A.G. Stam, S. Meijer, G. Giaccone, C.J. Meijer, R.J. Scheper, J. Wagstaff, J.B. Vermorken, and H.M. Pinedo, Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients, Ann. Oncol., 11(8): 965–970, 2000. [CSA], [CROSSREF]
  • J.B. Vermorken, A.M. Claessen, H. van Tinteren, H.E. Gall, R. Ezinga, S. Meijer, R.J. Scheper, C.J. Meijer, E. Bloemena, J.H. Ransom, M.G. Hanna, Jr., and H.M. Pinedo, Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial, Lancet, 353(9150): 345–350, 1999. [CSA], [CROSSREF]
  • B.C. Knight, B.E. Souberbielle, G.P. Rizzardi, S.E. Ball, and A.G. Dalgleish, Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine, Melanoma Res., 6(4): 299–306, 1996. [CSA]
  • M.C. Labarthe, N. Halanek, L. Birchall, N. Russell, C. Desel, S. Todryk, M.J. Peters, A. Lucas, F.W. Falkenberg, A.G. Dalgleish, M. Whelan, and S.J. Ward, The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model, Cancer Immunol. Immunother., 55(3): 277–288, 2006. [CSA], [CROSSREF]
  • E. Wang, R. Lichtenfels, J. Bukur, Y. Ngalame, M.C. Panelli, B. Seliger, and F.M. Marincola, Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer, Cancer Res., 64(20): 7279–7287, 2004. [CSA], [CROSSREF]
  • J.D. Eaton, M.J. Perry, S. Nicholson, M. Guckian, N. Russell, M. Whelan, and R.S. Kirby, Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer, BJU Int., 89(1): 19–26, 2002. [CSA]
  • M.S. Mitchell, J. Kan-Mitchell, R.A. Kempf, W. Harel, H.Y. Shau, and S. Lind, Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant, Cancer Res., 48(20): 5883–5893, 1988. [CSA]
  • D.L. Morton, L.J. Foshag, D.S. Hoon, J.A. Nizze, E. Famatiga, L.A. Wanek, C. Chang, D.G. Davtyan, R.K. Gupta, R. Elashoff, , et al., Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine, Ann. Surg., 216(4): 463–482, 1992. [CSA]
  • R. Vilella, D. Benitez, J. Mila, A. Vilalta, R. Rull, F. Cuellar, C. Conill, S. Vidal-Sicart, J. Costa, E. Yachi, J. Palou, J. Malvehy, S. Puig, R. Marti, B. Mellado, and T. Castel, Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine, Int. J. Cancer, 106(4): 626–631, 2003. [CSA], [CROSSREF]
  • A. Michael, G. Ball, N. Quatan, F. Wushishi, N. Russell, J. Whelan, P. Chakraborty, D. Leader, M. Whelan, and H. Pandha, Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables, Clin. Cancer Res., 11(12): 4469–4478, 2005. [CSA], [CROSSREF]
  • E.C. Hsueh, R. Essner, L.J. Foshag, D.W. Ollila, G. Gammon, S.J. O'Day, P.D. Boasberg, S.L. Stern, X. Ye, and D.L. Morton, Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine, J. Clin. Oncol., 20(23): 4549–4554, 2002. [CSA], [CROSSREF]
  • E.C. Hsueh, L. Nathanson, L.J. Foshag, R. Essner, J.A. Nizze, S.L. Stern, and D.L. Morton, Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases, Cancer, 85(10): 2160–2169, 1999. [CSA], [CROSSREF]
  • E.C. Hsueh, R.K. Gupta, K. Qi, and D.L. Morton, Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine, J. Clin. Oncol., 16(9): 2913–2920, 1998. [CSA]
  • K. Lang, F. Entschladen, C. Weidt, and K.S. Zaenker, Tumor immune escape mechanisms: Impact of the neuroendocrine system, Cancer Immunol. Immunother., 55(7): 749–760, 2006. [CSA], [CROSSREF]
  • J.N. Cormier, M.C. Panelli, J.A. Hackett, M.P. Bettinotti, A. Mixon, J. Wunderlich, L.L. Parker, N.P. Restifo, S. Ferrone, and F.M. Marincola, Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model, Int. J. Cancer, 80(5): 781–790, 1999. [CSA], [CROSSREF]
  • Y. Li, P. McGowan, I. Hellstrom, K.E. Hellstrom, and L. Chen, Costimulation of tumor-reactive CD4 + and CD8 + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma, J Immunol., 153(1): 421–428, 1994. [CSA]
  • L. Chen, S. Ashe, W.A. Brady, I. Hellstrom, K.E. Hellstrom, J.A. Ledbetter, P. McGowan, and P.S. Linsley, Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell, 71(7): 1093–1102, 1992. [CSA], [CROSSREF]
  • S. Baskar, N. Nabavi, L.H. Glimcher, and S. Ostrand-Rosenberg, Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity, J. Immunother., 14(3): 209–215, 1993. [CSA]
  • S.E. Townsend and J.P. Allison, Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells, Science, 259(5093): 368–370, 1993. [CSA], [CROSSREF]
  • D.J. Schendel, B. Frankenberger, P. Jantzer, S. Cayeux, E. Nobetaner, G. Willimsky, B. Maget, H. Pohla, and T. Blankenstein, Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse, Gene Ther., 7(23): 2007–2014, 2000. [CSA], [CROSSREF]
  • G.C. Meyer, R. Batrla, W. Rudy, S.C. Meuer, D. Wallwiener, B. Guckel, and U. Moebius, Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1 + -matched situation, Cancer Gene Ther., 6(3): 282–288, 1999. [CSA], [CROSSREF]
  • M.A. Imro, P. Dellabona, S. Manici, S. Heltai, G. Consogno, M. Bellone, C. Rugarli, and M.P. Protti, Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8 + cytotoxic T lymphocytes in vitro, Hum. Gene Ther., 9(9): 1335–1344, 1998. [CSA]
  • A. Dols, J.W. Smith, 2nd, S.L. Meijer, B.A. Fox, H.M. Hu, E. Walker, S. Rosenheim, T. Moudgil, T. Doran, W. Wood, M. Seligman, W.G. Alvord, D. Schoof, and W.J. Urba, Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results, Hum. Gene. Ther., 14(11): 1117–1123, 2003. [CSA], [CROSSREF]
  • L.E. Raez, P.A. Cassileth, J.J. Schlesselman, K. Sridhar, S. Padmanabhan, E.Z. Fisher, P.A. Baldie, and E.R. Podack, Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 22(14): 2800–2807, 2004. [CSA], [CROSSREF]
  • S.J. Antonia, J. Seigne, J. Diaz, C. Muro-Cacho, M. Extermann, M.J. Farmelo, M. Friberg, M. Alsarraj, J.J. Mahany, J. Pow-Sang, A. Cantor, and W. Janssen, Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma, J. Urol., 167(5): 1995–2000, 2002. [CSA], [CROSSREF]
  • P. Thompson, M. Fishman, J. Seigne, M. Dunn, W. Janssen, R. Smilee, M.J. Farmelo, D. Noyes, J. Pow Sang, and S. Antonia, Phase II study of B7-1 gene-modified autologous tumour cell vaccine and subcutaneous IL-2 for patients with stage IV renal cell carcinoma (RCC). J. Clin. Oncol., 23: 4502, 2005. [CSA]
  • B.J. Drucker, Renal cell carcinoma: Current status and future prospects, Cancer Treat. Rev., 31(7): 536–545, 2005. [CSA], [CROSSREF]
  • I. Komenaka, H. Hoerig, and H.L. Kaufman, Immunotherapy for melanoma, Clin. Dermatol., 22(3): 251–265, 2004. [CSA], [CROSSREF]
  • I. Hara, H. Nguyen, Y. Takechi, B. Gansbacher, P.B. Chapman, and A.N. Houghton, Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection, Int. J. Cancer, 61(2): 253–260, 1995. [CSA]
  • K. Zatloukal, A. Schneeberger, M. Berger, W. Schmidt, F. Koszik, R. Kutil, M. Cotten, E. Wagner, M. Buschle, G. Maass, , et al., Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters, J. Immunol., 154(7): 3406–3419, 1995. [CSA]
  • B. Gansbacher, K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity, J. Exp. Med., 172(4): 1217–1224, 1990. [CSA], [CROSSREF]
  • E.R. Fearon, D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response, Cell, 60(3): 397–403, 1990. [CSA], [CROSSREF]
  • D.B. Moody, J.C. Robinson, C.M. Ewing, A.J. Lazenby, and W.B. Isaacs, Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo, Prostate, 24(5): 244–251, 1994. [CSA]
  • R. Bannerji, C.D. Arroyo, C. Cordon-Cardo, and E. Gilboa, The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity, J. Immunol., 152(5): 2324–2332, 1994. [CSA]
  • G. Maass, W. Schmidt, M. Berger, F. Schilcher, F. Koszik, A. Schneeberger, G. Stingl, M.L. Birnstiel, and T. Schweighoffer, Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination, Proc. Natl. Acad. Sci. U.S.A., 92(12): 5540–5544, 1995. [CSA]
  • H. Veelken, A. Mackensen, M. Lahn, G. Kohler, D. Becker, B. Franke, U. Brennscheidt, P. Kulmburg, F.M. Rosenthal, H. Keller, J. Hasse, W. Schultze-Seemann, E.H. Farthmann, R. Mertelsmann, and A. Lindemann, A phase-I Clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer, Int. J. Cancer, 70(3): 269–277, 1997. [CSA], [CROSSREF]
  • S. Osanto, P.P. Schiphorst, N.I. Weijl, N. Dijkstra, A. Van Wees, N. Brouwenstein, N. Vaessen, J. H. Van Krieken, J. Hermans, F.J. Cleton, and P.I. Schrier, Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line, Hum. Gene Ther., 11(5): 739–750, 2000. [CSA], [CROSSREF]
  • F. Arienti, J. Sule-Suso, F. Belli, L. Mascheroni, L. Rivoltini, C. Melani, M. Maio, N. Cascinelli, M.P. Colombo, and G. Parmiani, Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells, Hum. Gene Ther., 7(16): 1955–1963, 1996. [CSA]
  • K. Palmer, J. Moore, M. Everard, J.D. Harris, S. Rodgers, R.C. Rees, A.K. Murray, R. Mascari, J. Kirkwood, P.G. Riches, C. Fisher, J.M. Thomas, M. Harries, S.R. Johnston, M.K. Collins, and M.E. Gore, Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma, Hum. Gene. Ther., 10(8): 1261–1268, 1999. [CSA], [CROSSREF]
  • M. Maio, E. Fonsatti, E. Lamaj, M. Altomonte, I. Cattarossi, C. Santantonio, C. Melani, F. Belli, F. Arienti, M.P. Colombo, and G. Parmiani, Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells, Cancer Immunol. Immunother., 51(1): 9–14, 2002. [CSA], [CROSSREF]
  • F. Belli, F. Arienti, J. Sule-Suso, C. Clemente, L. Mascheroni, A. Cattelan, C. Santantonio, G.F. Gallino, C. Melani, S. Rao, M.P. Colombo, M. Maio, N. Cascinelli, and G. Parmiani, Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability, Cancer Immunol. Immunother., 44(4): 197–203, 1997. [CSA], [CROSSREF]
  • G. Pizza, C. De Vinci, G. Lo Conte, A. Mazzuca, V. Di Maio, S. Ratini, G. Severini, L. Busutti, A.P. Palareti, A. Gulino, A. Vacca, L. Melchiorri, M. Ferrari, L. Giacomelli, O.R. Baricordi, S. Forzini, and R. Capanna, Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II, Folia Biol. (Praha), 50(6): 175–183, 2004. [CSA]
  • F. Pericle, M. Giovarelli, M.P. Colombo, G. Ferrari, P. Musiani, A. Modesti, F. Cavallo, F. Di Pierro, F. Novelli, and G. Forni, An efficient Th2-type memory follows CD8 + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4, J. Immunol., 153(12): 5659–5673, 1994. [CSA]
  • R.I. Tepper, P.K. Pattengale, and P. Leder, Murine interleukin-4 displays potent anti-tumor activity in vivo, Cell, 57(3): 503–512, 1989. [CSA], [CROSSREF]
  • P.T. Golumbek, A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4, Science, 254(5032): 713–716, 1991. [CSA], [CROSSREF]
  • R.I. Tepper, R.L. Coffman, and P. Leder, An eosinophil-dependent mechanism for the antitumor effect of interleukin-4, Science, 257(5069): 548–551, 1992. [CSA], [CROSSREF]
  • J. Eguchi, N. Kuwashima, M. Hatano, F. Nishimura, J.E. Dusak, W.J. Storkus, and H. Okada, IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity, J. Immunol., 174(11): 7194–7201, 2005. [CSA]
  • F. Arienti, F. Belli, F. Napolitano, J. Sule-Suso, A. Mazzocchi, G.F. Gallino, A. Cattelan, C. Santantonio, L. Rivoltini, C. Melani, M.P. Colombo, N. Cascinelli, M. Maio, and G. Parmiani, Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells, Hum. Gene Ther., 10(18): 2907–2916, 1999. [CSA], [CROSSREF]
  • H. Ikeda, L.J. Old, and R.D. Schreiber, The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev., 13(2): 95–109, 2002. [CSA], [CROSSREF]
  • Z. Abdel-Wahab, M. Dar, S. Osanto, T. Fong, C.E. Vervaert, D. Hester, D. Jolly, and H.F. Seigler, Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon, Cancer Gene Ther., 4(1): 33–41, 1997. [CSA]
  • R.S. Wu, J.J. Kobie, D.G. Besselsen, T.C. Fong, V.D. Mack, J.A. McEarchern, and E.T. Akporiaye, Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma, Cancer Immunol. Immunother., 50(5): 229–240, 2001. [CSA], [CROSSREF]
  • Y. Watanabe, K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata, Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity, Proc. Natl. Acad. Sci. U.S.A., 86(23): 9456–9460, 1989. [CSA], [CROSSREF]
  • M.M. Dar, Z. Abdel-Wahab, C.E. Vervaert, T. Darrow, J. Barber, and H.F. Seigler, Immunological memory induced by genetically transduced tumor cells, Ann. Surg. Oncol., 3(3): 247–254, 1996. [CSA], [CROSSREF]
  • F.M. Rosenthal, K. Cronin, R. Bannerji, D.W. Golde, and B. Gansbacher, Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs, Blood, 83(5): 1289–1298, 1994. [CSA]
  • K.S. Zier and B. Gansbacher, Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells, Eur. J. Cancer, 32A(8): 1408–1412, 1996. [CSA], [CROSSREF]
  • Z. Abdel-Wahab, C. Weltz, D. Hester, N. Pickett, C. Vervaert, J.R. Barber, D. Jolly, and H.F. Seigler, A Phase I Clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response, Cancer, 80(3): 401–412, 1997. [CSA], [CROSSREF]
  • N. Mach and G. Dranoff, Cytokine-secreting tumor cell vaccines, Curr. Opin. Immunol., 12(5): 571–575, 2000. [CSA], [CROSSREF]
  • C. De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, P. Musiani, F. Cavallo, P. Nanni, and P.L. Lollini, Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine, Cancer Res., 64(11): 4001–4009, 2004. [CSA], [CROSSREF]
  • G.W. Hull, M.A. McCurdy, Y. Nasu, C.H. Bangma, G. Yang, S. Shimura, H.M. Lee, J. Wang, J. Albani, S. Ebara, T. Sato, T.L. Timme, and T.C. Thompson, Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines, Clin. Cancer Res., 6(10): 4101–4109, 2000. [CSA]
  • Y. Sun, K. Jurgovsky, P. Moller, S. Alijagic, T. Dorbic, J. Georgieva, B. Wittig, and D. Schadendorf, Vaccination with IL-12 gene-modified autologous melanoma cells: PreClinical results and a first Clinical phase I study, Gene Ther., 5(4): 481–490, 1998. [CSA], [CROSSREF]
  • N. Fuji, H. Fujiwara, Y. Ueda, F. Taniguchi, T. Yoshimura, T. Oka, and H. Yamagishi, Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12, Gene Ther., 6(6): 1120–1127, 1999. [CSA], [CROSSREF]
  • H. Ehlken, D. Schadendorf, and S. Eichmuller, Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells, Int. J. Cancer, 108(2): 307–313, 2004. [CSA], [CROSSREF]
  • P. Moller, H. Moller, Y. Sun, T. Dorbic, B.M. Henz, B. Wittig, and D. Schadendorf, Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells, Cancer Gene Ther., 7(7): 976–984, 2000. [CSA], [CROSSREF]
  • R. Meazza, P.L. Lollini, P. Nanni, C. De Giovanni, A. Gaggero, A. Comes, M. Cilli, E. Di Carlo, S. Ferrini, and P. Musiani, Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response, Int. J. Cancer, 87(4): 574–581, 2000. [CSA], [CROSSREF]
  • H.L. Ma, M.J. Whitters, R.F. Konz, M. Senices, D.A. Young, M.J. Grusby, M. Collins, and K. Dunussi-Joannopoulos, IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma, J. Immunol., 171(2): 608–615, 2003. [CSA]
  • A. Moroz, C. Eppolito, Q. Li, J. Tao, C.H. Clegg, and P.A. Shrikant, IL-21 enhances and sustains CD8 + T cell responses to achieve durable tumor immunity: Comparative evaluation of IL-2, IL-15, and IL-21, J. Immunol., 173(2): 900–909, 2004. [CSA]
  • A. Comes, O. Rosso, A.M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M.P. Colombo, and S. Ferrini, CD25 + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine, J. Immunol., 176(3): 1750–1758, 2006. [CSA]
  • E. Di Carlo, A. Comes, A.M. Orengo, O. Rosso, R. Meazza, P. Musiani, M.P. Colombo, and S. Ferrini, IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice, J. Immunol., 172(3): 1540–1547, 2004. [CSA]
  • C.H. Lo, S.C. Lee, P.Y. Wu, W.Y. Pan, J. Su, C.W. Cheng, S.R. Roffler, B.L. Chiang, C.N. Lee, C.W. Wu, and M.H. Tao, Antitumor and antimetastatic activity of IL-23, J. Immunol., 171(2): 600–607, 2003. [CSA]
  • S. Oniki, H. Nagai, T. Horikawa, J. Furukawa, M. L. Belladonna, T. Yoshimoto, I. Hara, and C. Nishigori, Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma, Cancer Res., 66(12): 6395–6404, 2006. [CSA], [CROSSREF]
  • Y.Q. Wang, S. Ugai, O. Shimozato, L. Yu, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, and M. Tagawa, Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells, Int. J. Cancer, 105(6): 820–824, 2003. [CSA], [CROSSREF]
  • M. Chiyo, O. Shimozato, L. Yu, K. Kawamura, T. Iizasa, T. Fujisawa, and M. Tagawa, Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals, Int. J. Cancer, 115(3): 437–442, 2005. [CSA], [CROSSREF]
  • M. Hisada, S. Kamiya, K. Fujita, M.L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto, Potent antitumor activity of interleukin-27, Cancer Res., 64(3): 1152–1156, 2004. [CSA], [CROSSREF]
  • R. Salcedo, J.K. Stauffer, E. Lincoln, T.C. Back, J.A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein, and J.M. Wigginton, IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8 + T cells, J. Immunol., 173(12): 7170–7182, 2004. [CSA]
  • V.K. Sondak and J.A. Sosman, Results of Clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine, Semin. Cancer Biol., 13(6): 409–415, 2003. [CSA], [CROSSREF]
  • V.K. Sondak, P.Y. Liu, R.J. Tuthill, R.A. Kempf, J.M. Unger, J.A. Sosman, J.A. Thompson, G.R. Weiss, B.G. Redman, J.G. Jakowatz, R.D. Noyes, and L.E. Flaherty, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group, J. Clin. Oncol., 20(8): 2058–2066, 2002. [CSA], [CROSSREF]
  • V.K. Sondak, J. Sosman, J.M. Unger, P.Y. Liu, J. Thompson, R. Tuthill, R. Kempf, L. Flaherty, S. O. G. (SWOG). Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035, 2004. [CSA]
  • M. Fishman and S. Antonia, Specific antitumour vaccine for renal cancer, Lancet, 363(9409): 583–584, 2004. [CSA], [CROSSREF]
  • S. Kommu, Renal-cell carcinoma: Vaccination and risk of tumour progression, Lancet, 363(9420): 1557; author reply 1557, 2004. [CSA]
  • M.L. Albert, B. Sauter, and N. Bhardwaj, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392(6671): 86–89, 1998. [CSA], [CROSSREF]
  • R.M. Steinman, S. Turley, I. Mellman, and K. Inaba, The induction of tolerance by dendritic cells that have captured apoptotic cells, J. Exp. Med., 191(3): 411–416, 2000. [CSA], [CROSSREF]
  • H. Pandha, J. Eaton, R. Greenhalgh, D. Soars, and A. Dalgleish, Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy, Cancer Gene Ther., 12(6): 572–578, 2005. [CSA], [CROSSREF]
  • J.D. Eaton, M.J. Perry, S.M. Todryk, R.A. Mazucco, R.S. Kirby, J.R. Griffiths, and A.G. Dalgleish, Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques, Gene Ther., 8(7): 557–567, 2001. [CSA], [CROSSREF]
  • V. Schirrmacher, Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory, Cancer Immunol. Immunother., 54(6): 587–598, 2005. [CSA], [CROSSREF]
  • D. Ockert, V. Schirrmacher, N. Beck, E. Stoelben, T. Ahlert, J. Flechtenmacher, E. Hagmuller, R. Buchcik, M. Nagel, and H.D. Saeger, Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma, Clin. Cancer Res., 2(1): 21–28, 1996. [CSA]
  • W. Bohle, P. Schlag, W. Liebrich, P. Hohenberger, M. Manasterski, P. Moller, and V. Schirrmacher, Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First Clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus, Cancer, 66(7): 1517–1523, 1990. [CSA]
  • B.T. Patel, M.B. Lutz, P. Schlag, and V. Schirrmacher, An analysis of autologous T-cell anti-tumour responses in colon-carcinoma patients following active specific immunization (ASI) Int. J. Cancer, 51(6): 878–885, 1992. [CSA]
  • K. Dredge, J.B. Marriott, S.M. Todryk, G.W. Muller, R. Chen, D.I. Stirling, and A.G. Dalgleish, Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity, J. Immunol., 168(10): 4914–4919, 2002. [CSA]
  • J.P. Machiels, R.T. Reilly, L.A. Emens, A.M. Ercolini, R.Y. Lei, D. Weintraub, F.I. Okoye, and E.M. Jaffee, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, Cancer Res., 61(9): 3689–3697, 2001. [CSA]
  • R.A. Prell, L. Gearin, A. Simmons, M. Vanroey, and K. Jooss, The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration, Cancer Immunol. Immunother., 55(10): 1285–1293, 2006. [CSA], [CROSSREF]
  • Y. Chu, L.X. Wang, G. Yang, H.J. Ross, W.J. Urba, R. Prell, K. Jooss, S. Xiong, and H.M. Hu, Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma, J. Immunother., 29(4): 367–380, 2006. [CSA], [CROSSREF]
  • B. Yu, S. Kusmartsev, F. Cheng, M. Paolini, Y. Nefedova, E. Sotomayor, and D. Gabrilovich, Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer, Clin. Cancer Res., 9(1): 285–294, 2003. [CSA]
  • T. Hahn, I. Alvarez, J.J. Kobie, L. Ramanathapuram, S. Dial, A. Fulton, D. Besselsen, E. Walker, and E. T. Akporiaye, Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer, Int. J. Cancer, 118(9): 2220–2231, 2006. [CSA], [CROSSREF]
  • A.R. Haas, J. Sun, A. Vachani, A.F. Wallace, M. Silverberg, V. Kapoor, and S.M. Albelda, Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine, Clin. Cancer Res., 12(1): 214–222, 2006. [CSA], [CROSSREF]
  • L.J. Jia, H.M. Xu, D.Y. Ma, Q.G. Hu, X.F. Huang, W.H. Jiang, S.F. Li, K.Z. Jia, Q.L. Huang, and Z.C. Hua, Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model, Cancer Biol. Ther., 4(8): 840–845, 2005. [CSA]
  • B.I. Rini, V. Weinberg, L. Fong, S. Conry, R.M. Hershberg, and E.J. Small, Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy, Cancer, 107(1): 67–74, 2006. [CSA], [CROSSREF]
  • S. Demaria, N. Bhardwaj, W.H. McBride, and S.C. Formenti, Combining radiotherapy and immunotherapy: A revived partnership, Int. J. Radiat. Oncol. Biol. Phys., 63(3): 655–666, 2005. [CSA], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.